Status:
TERMINATED
Voriconazole as Prophylactic Therapy in Lung Transplant Recipients
Lead Sponsor:
University of Chicago
Collaborating Sponsors:
Pfizer
Conditions:
Infection
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to compare the safety and efficacy of Voriconazole with Itraconazole following lung transplantation.
Detailed Description
All participants will receive itraconazole during their inpatient post transplant stay. As an outpatient, ten subjects will be randomized to receive itraconazole 200mg orally once daily for 6 month an...
Eligibility Criteria
Inclusion
- Bilateral-lung or single-lung transplant recipients between the ages of 18- 65 years old.
- Patients must be able to give informed consent prior to and again after transplantation
Exclusion
- Lung transplant patients unable to give informed consent.
- Prior adverse reaction to the drug itraconazole or voriconazole
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00455364
Start Date
April 1 2007
End Date
April 1 2007
Last Update
February 6 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Chicago
Chicago, Illinois, United States, 60637